Biomarkers /
INPP4A
Overview
INPP4A is altered in 1.32% of all cancers with lung adenocarcinoma, endometrial endometrioid adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in INPP4A are INPP4A Mutation (1.10%), INPP4A Amplification (0.10%), INPP4A Loss (0.02%), INPP4A R938Q (0.02%), and INPP4A A753T (0.01%) [3].
Clinical Trials
Significance of INPP4A in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.